Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships

Molecular Oncology

Volumn 10, Issue 2, 2016, Pages 360-370

  Sakr, Rita A ^a   Schizas, Michail ^a   Carniello, Jose V Scarpa ^a   Ng, Charlotte K Y ^a   Piscuoglio, Salvatore ^a   Giri, Dilip ^a   Andrade, Victor P ^a   de Brot, Marina ^a   Lim, Raymond S ^a   Towers, Russell ^a   Weigelt, Britta ^a   Reis Filho, Jorge S ^a   King, Tari A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clonality; Invasive lobular carcinoma; Lobular carcinoma in situ; Massively parallel sequencing; Somatic genetic alterations

Indexed keywords

FIZZY RELATED PROTEIN; CADHERIN; CBFB PROTEIN, HUMAN; CDH1 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; CORE BINDING FACTOR BETA; FIBROCYSTIN -L, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ARTICLE; BIOINFORMATICS; BREAST CARCINOMA; CLINICAL ARTICLE; DNA EXTRACTION; DNA REPAIR; EXON; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MICRODISSECTION; PRECURSOR; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; TUMOR INVASION; BREAST TUMOR; CARCINOMA IN SITU; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG CARCINOMA; MUTATION; PATHOLOGY;

BREAST NEOPLASMS; CADHERINS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; COHORT STUDIES; CORE BINDING FACTOR BETA SUBUNIT; EXONS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, CELL SURFACE;

EID: 84958877467     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.11.001     Document Type: Article

References (51)

1. Andrade V.P., Ostrovnaya I., Seshan V.E., Morrogh M., Giri D., Olvera N., De Brot M., Morrow M., Begg C.B., King T.A. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res. 2012, 14:R103.
2. Banerji S., Cibulskis K., Rangel-Escareno C., Brown K.K., Carter S.L., Frederick A.M., Lawrence M.S., Sivachenko A.Y., Sougnez C., Zou L., Cortes M.L., Fernandez-Lopez J.C., Peng S., Ardlie K.G., Auclair D., Bautista-Pina V., Duke F., Francis J., Jung J., Maffuz-Aziz A., Onofrio R.C., Parkin M., Pho N.H., Quintanar-Jurado V., Ramos A.H., Rebollar-Vega R., Rodriguez-Cuevas S., Romero-Cordoba S.L., Schumacher S.E., Stransky N., Thompson K.M., Uribe-Figueroa L., Baselga J., Beroukhim R., Polyak K., Sgroi D.C., Richardson A.L., Jimenez-Sanchez G., Lander E.S., Gabriel S.B., Garraway L.A., Golub T.R., Melendez-Zajgla J., Toker A., Getz G., Hidalgo-Miranda A., Meyerson M. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409.
3. Berx G., Cleton-Jansen A.M., Strumane K., de Leeuw W.J., Nollet F., van Roy F., Cornelisse C. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996, 13:1919-1925.
4. Bratthauer G.L., Tavassoli F.A. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Archiv. 2002, 440:134-138.
5. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
6. Carter H., Chen S., Isik L., Tyekucheva S., Velculescu V.E., Kinzler K.W., Vogelstein B., Karchin R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009, 69:6660-6667.
7. Chandarlapaty S., Sakr R.A., Giri D., Patil S., Heguy A., Morrow M., Modi S., Norton L., Rosen N., Hudis C., King T.A. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin. Cancer Res. 2012, 18:6784-6791.
8. Cheng D.T., Mitchell T.N., Zehir A., Shah R.H., Benayed R., Syed A., Chandramohan R., Liu Z.Y., Won H.H., Scott S.N., Brannon A.R., O'Reilly C., Sadowska J., Casanova J., Yannes A., Hechtman J.F., Yao J., Song W., Ross D.S., Oultache A., Dogan S., Borsu L., Hameed M., Nafa K., Arcila M.E., Ladanyi M., Berger M.F. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. The J. Mol. Diagn. 2015, 17:251-264.
9. Choi Y., Sims G.E., Murphy S., Miller J.R., Chan A.P. Predicting the functional effect of amino acid substitutions and indels. PloS one 2012, 7:e46688.
10. Cibulskis K., Lawrence M.S., Carter S.L., Sivachenko A., Jaffe D., Sougnez C., Gabriel S., Meyerson M., Lander E.S., Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013, 31:213-219.
11. Ciriello G., Gatza M.L., Hoadley K.A., Zhang H., Rhie S.K., Bowlby R., Wilkerson M.D., Kandoth C., McLellan M., Cherniack A., Laird P.W., Sander C., King T.A., Perou C.M. Abstract S2-04: Comprehensive molecular characterization of invasive lobular breast tumors. Cancer Res. 2014, 75:S2-S04.
12. Ciriello G., Gatza M.L., Beck A.H., Wilkerson M.D., Rhie S.K., Pastore A., Zhang H., McLellan M., Yau C., Kandoth C., Bowlby R., Shen H., Hayat S., Fieldhouse R., Lester S.C., Tse G.M.K., Factor R.E., Collins L.C., Allison K.H., Chen Y.Y., Jensen K., Johnson N.B., Oesterreich S., Mills G.B., Cherniack A.D., Robertson G., Benz C., Sander C., Laird P.W., Perou C.M. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 2015, 163:506-519.
13. Dabbs D.J., Schnitt S.J., Geyer F.C., Weigelt B., Baehner F.L., Decker T., Eusebi V., Fox S.B., Ichihara S., Lakhani S.R., Palacios J., Rakha E., Richardson A.L., Schmitt F.C., Tan P.H., Tse G.M., Vincent-Salomon A., Ellis I.O., Badve S., Reis-Filho J.S. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am. J. Surg. Pathol. 2013, 37:e1-11.
14. De Brot M., Andrade V.P., Morrogh M., Berger M.F., Won H.H., Koslow M.S., Qin L.-X., Giri D.D., Olvera N., Sakr R.A., King T.A. Novel Mutations in Lobular Carcinoma in Situ (LCIS) as Uncovered by Targeted Parallel sequencing., Thirty-fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium 2012, Cancer Res, San Antonio, TX, pp. Abstract nr PD05-02.
15. De Leeuw W.J., Berx G., Vos C.B., Peterse J.L., Van de Vijver M.J., Litvinov S., Van Roy F., Cornelisse C.J., Cleton-Jansen A.M. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J. Pathol. 1997, 183:404-411.
16. Ding J., Bashashati A., Roth A., Oloumi A., Tse K., Zeng T., Haffari G., Hirst M., Marra M.A., Condon A., Aparicio S., Shah S.P. Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics 2012, 28:167-175.
17. Droufakou S., Deshmane V., Roylance R., Hanby A., Tomlinson I., Hart I.R. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. j. Cancer 2001, 92:404-408.
18. Ellis M.J., Ding L., Shen D., Luo J., Suman V.J., Wallis J.W., Van Tine B.A., Hoog J., Goiffon R.J., Goldstein T.C., Ng S., Lin L., Crowder R., Snider J., Ballman K., Weber J., Chen K., Koboldt D.C., Kandoth C., Schierding W.S., McMichael J.F., Miller C.A., Lu C., Harris C.C., McLellan M.D., Wendl M.C., DeSchryver K., Allred D.C., Esserman L., Unzeitig G., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Leitch M., Hunt K., Olson J., Tao Y., Maher C.A., Fulton L.L., Fulton R.S., Harrison M., Oberkfell B., Du F., Demeter R., Vickery T.L., Elhammali A., Piwnica-Worms H., McDonald S., Watson M., Dooling D.J., Ota D., Chang L.W., Bose R., Ley T.J., Piwnica-Worms D., Stuart J.M., Wilson R.K., Mardis E.R. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
19. Foote F.W., Stewart F.W. Lobular carcinoma in situ: a rare form of mammary cancer. Am. J. Pathol. 1941, 17. 491-496 493.
20. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
21. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., Cerami E., Sander C., Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:pl1.
22. Haagensen C.D., Lane N., Lattes R., Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978, 42:737-769.
23. Hwang E.S., Nyante S.J., Yi Chen Y., Moore D., DeVries S., Korkola J.E., Esserman L.J., Waldman F.M. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004, 100:2562-2572.
24. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., Leiserson M.D., Miller C.A., Welch J.S., Walter M.J., Wendl M.C., Ley T.J., Wilson R.K., Raphael B.J., Ding L. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
25. Koboldt D.C., Zhang Q., Larson D.E., Shen D., McLellan M.D., Lin L., Miller C.A., Mardis E.R., Ding L., Wilson R.K. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012, 22:568-576.
26. WHO Classification of Breast Tumors 2012, IARC, Lyon. S.R. Lakhani, I.O. Ellis, S.J. Schnitt, P.H. Tan, M.J. van de Vijver (Eds.).
27. Lakhani S.R., Audretsch W., Cleton-Jensen A.M., Cutuli B., Ellis I., Eusebi V., Greco M., Houslton R.S., Kuhl C.K., Kurtz J., Palacios J., Peterse H., Rochard F., Rutgers E., Eusoma The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. Eur. J. Cancer 2006, 42:2205-2211.
28. Lakhani S.R., Collins N., Sloane J.P., Stratton M.R. Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin. Mol. Pathol. 1995, 48:M74-M78.
29. Larson D.E., Harris C.C., Chen K., Koboldt D.C., Abbott T.E., Dooling D.J., Ley T.J., Mardis E.R., Wilson R.K., Ding L. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 2012, 28:311-317.
30. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
31. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
32. Logan G.J., Dabbs D.J., Lucas P.C., Jankowitz R.C., Brown D.D., Clark B.Z., Oesterreich S., McAuliffe P.F. Molecular drivers of lobular carcinoma in situ. Breast Cancer Res. 2015, 17:76.
33. Lopez-Garcia M.A., Geyer F.C., Lacroix-Triki M., Marchio C., Reis-Filho J.S. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology 2010, 57:171-192.
34. Martelotto L.G., Ng C., De Filippo M.R., Zhang Y., Piscuoglio S., Lim R., Shen R., Norton L., Reis-Filho J.S., Weigelt B. Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biol. 2014, 15:484.
35. Mastracci T.L., Shadeo A., Colby S.M., Tuck A.B., O'Malley F.P., Bull S.B., Lam W.L., Andrulis I.L. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast. Genes chromosomes cancer 2006, 45:1007-1017.
36. McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010, 20:1297-1303.
37. Morandi L., Marucci G., Foschini M.P., Cattani M.G., Pession A., Riva C., Eusebi V. Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch. 2006, 449:14-23.
38. Natrajan R., Wilkerson P.M., Marchio C., Piscuoglio S., Ng C.K., Wai P., Lambros M.B., Samartzis E.P., Dedes K.J., Frankum J., Bajrami I., Kopec A., Mackay A., A'Hern R., Fenwick K., Kozarewa I., Hakas J., Mitsopoulos C., Hardisson D., Lord C.J., Kumar-Sinha C., Ashworth A., Weigelt B., Sapino A., Chinnaiyan A.M., Maher C.A., Reis-Filho J.S. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J. Pathol. 2014, 232:553-565.
39. Page D.L., Kidd T.E., Dupont W.D., Simpson J.F., Rogers L.W. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum. Pathol. 1991, 22:1232-1239.
40. Rieger-Christ K.M., Pezza J.A., Dugan J.M., Braasch J.W., Hughes K.S., Summerhayes I.C. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol. Pathol. 2001, 54:91-97.
41. Robinson J.T., Thorvaldsdottir H., Winckler W., Guttman M., Lander E.S., Getz G., Mesirov J.P. Integrative genomics viewer. Nat. Biotechnol. 2011, 29:24-26.
42. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J.S., Malmstrom P.O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A., Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005, 65:2554-2559.
43. Sakr R.A., Weigelt B., Chandarlapaty S., Andrade V.P., Guerini-Rocco E., Giri D., Ng C.K., Cowell C.F., Rosen N., Reis-Filho J.S., King T.A. PI3K pathway activation in high-grade ductal carcinoma in situ-implications for progression to invasive breast carcinoma. Clin. Cancer Res. 2014, 20:2326-2337.
44. Schwarz J.M., Rodelsperger C., Schuelke M., Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 2010, 7:575-576.
45. Shihab H.A., Gough J., Cooper D.N., Stenson P.D., Barker G.L., Edwards K.J., Day I.N., Gaunt T.R. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Hum. Mutat. 2013, 34:57-65.
46. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., Carey M., Hu Z., Guan Y., Sahin A., Symmans W.F., Pusztai L., Nolden L.K., Horlings H., Berns K., Hung M.C., van de Vijver M.J., Valero V., Gray J.W., Bernards R., Mills G.B., Hennessy B.T. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68:6084-6091.
47. Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., Wedge D.C., Nik-Zainal S., Martin S., Varela I., Bignell G.R., Yates L.R., Papaemmanuil E., Beare D., Butler A., Cheverton A., Gamble J., Hinton J., Jia M., Jayakumar A., Jones D., Latimer C., Lau K.W., McLaren S., McBride D.J., Menzies A., Mudie L., Raine K., Rad R., Chapman M.S., Teague J., Easton D., Langerod A., Oslo Breast Cancer C., Lee M.T., Shen C.Y., Tee B.T., Huimin B.W., Broeks A., Vargas A.C., Turashvili G., Martens J., Fatima A., Miron P., Chin S.F., Thomas G., Boyault S., Mariani O., Lakhani S.R., van de Vijver M., van 't Veer L., Foekens J., Desmedt C., Sotiriou C., Tutt A., Caldas C., Reis-Filho J.S., Aparicio S.A., Salomon A.V., Borresen-Dale A.L., Richardson A.L., Campbell P.J., Futreal P.A., Stratton M.R. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404.
48. Vos C.B., Cleton-Jansen A.M., Berx G., de Leeuw W.J., ter Haar N.T., van Roy F., Cornelisse C.J., Peterse J.L., van de Vijver M.J. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br. J. Cancer 1997, 76:1131-1133.
49. Wagle N., Berger M.F., Davis M.J., Blumenstiel B., Defelice M., Pochanard P., Ducar M., Van Hummelen P., Macconaill L.E., Hahn W.C., Meyerson M., Gabriel S.B., Garraway L.A. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012, 2:82-93.
50. Wagner P.L., Kitabayashi N., Chen Y.T., Shin S.J. Clonal relationship between closely approximated low-grade ductal and lobular lesions in the breast: a molecular study of 10 cases. Am. J. Clin. Pathol. 2009, 132:871-876.
51. Weinreb I., Piscuoglio S., Martelotto L.G., Waggott D., Ng C.K., Perez-Ordonez B., Harding N.J., Alfaro J., Chu K.C., Viale A., Fusco N., da Cruz Paula A., Marchio C., Sakr R.A., Lim R., Thompson L.D., Chiosea S.I., Seethala R.R., Skalova A., Stelow E.B., Fonseca I., Assaad A., How C., Wang J., de Borja R., Chan-Seng-Yue M., Howlett C.J., Nichols A.C., Wen Y.H., Katabi N., Buchner N., Mullen L., Kislinger T., Wouters B.G., Liu F.F., Norton L., McPherson J.D., Rubin B.P., Clarke B.A., Weigelt B., Boutros P.C., Reis-Filho J.S. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat. Genet. 2014, 46:1166-1169.